The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Haha, well I hope you’re right..
At this rate I wonder if the MCAP will hit £500m and the share price will still be 20p (said tongue in cheek - well kind of..)
Appointment of Joint Broker
Manchester, UK - 29 July 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as joint broker with immediate effect.
Cairn Financial Advisors LLP will continue as the Company's nominated adviser and Stifel Nicolaus Europe Limited will continue as the Company's joint broker.
All other shares so the previous days closed..
Not sure what to read in to this (if anything), but just checked Spreadex and it’s not showing any prices for Synairgen, instead it’s saying ‘Phone for Quotes’ never seen this before (I’ve seen it with the phone symbols but still showing bid/offer).
Great hews this morning and adds more valuation to this JV that I posted about from Myles’s 3rd paper mid-June
=========
I found the third paragraph of the section below to be really interesting from Myles’s research note published this week. I feel this could be under the radar of many investors and it all be interesting to see:
A) How soon Serie A fundraising happens
B) what valuation is given to AffyXell
“Whilst Avacta’s first three collaborations are based on licensing deals, Avacta and Daewoong have created a new joint venture company, named AffyXell (Avacta holds a 45% equity stake).
Although the JV is only at an embryonic stage, we note how other early stage biotech companies specialising in gene and/or cell therapies have attracted dizzying valuations in recent years.
We believe that AffyXell will shortly be seeking external funding in a Series A round, which will provide an exact valuation for Avacta’s existing 45% stake.”
I’ve kept all 150k shares from 50p average - long way to go on this yet..
Thank you Myles, I appreciate your reply, and yes all good thanks, hope to and yours are too.
Thanks for all your free shared papers, they helped me along the way.
Exciting times ahead in the near term, for me it’s a hold for a year and see where we get to (wish I could trade like some, but I don’t have the time or the skill!)
GLA
Thanks Myles, good points as ever. I wondered if you had a view on the below paragraph from your research note published recently. I feel this could be under the radar of many investors, what are you thoughts on these two questions:
A) When do you think the Series A fundraising will happen?
B) what approx valuation will be given to AffyXell?
“Whilst Avacta’s first three collaborations are based on licensing deals, Avacta and Daewoong have created a new joint venture company, named AffyXell (Avacta holds a 45% equity stake).
Although the JV is only at an embryonic stage, we note how other early stage biotech companies specialising in gene and/or cell therapies have attracted dizzying valuations in recent years.
We believe that AffyXell will shortly be seeking external funding in a Series A round, which will provide an exact valuation for Avacta’s existing 45% stake.”
I’ve just bought back in here today having sold down
a couple of months ago to deploy in AVCT & SNG.
Now holding for the next 12-18 months when I would expect the SP to be significantly higher.
Fingers crossed.
Thanks gents, yes SNG was definitely a case of research research research and then ignore the SP and the negative posters and keep the faith in the science, it was certainly a great start to the week at 7am today!
Other than that the SNG board had lots of very good research posters, which is the case here too.
I tend to be a lurker, as I don’t profess to know anything about the technical details to add in. Thanks for your offer of answering questions, that’s appreciated.
Here’s hoping my luck does carry over to here too!
Hi all,
After seeing this tipped (Doggy I think - or his neighbour?!), and researched, including all your messages this year - thank you.
I’ve taken some profit from SYNG this morning and invested in here.
Let’s see what the next few months brings.
GLA.
Great idea - good to have some fun :-)
£1.07
According to IG Index just now, 251 – 500 IG client accounts have open positions in this market and 100% of IG client accounts with open positions in this market expect the price to rise.
Spreadex is still showing as 94% are long on AVCT with no numbers given for amount of people with positions.
Apologies! I’m sure it just showed 100, it is 92 on
Spreadex
Not sure if you need an account to see that data.
(not a Ramper)
According to Spreadex, 100percent of clients are now long. It was 90 earlier this week.
I found the third paragraph of the section below to be really interesting from Myles’s research note published this week. I feel this could be under the radar of many investors and it all be interesting to see:
A) How soon Serie A fundraising happens
B) what valuation is given to AffyXell
“Whilst Avacta’s first three collaborations are based on licensing deals, Avacta and Daewoong have created a new joint venture company, named AffyXell (Avacta holds a 45% equity stake).
Although the JV is only at an embryonic stage, we note how other early stage biotech companies specialising in gene and/or cell therapies have attracted dizzying valuations in recent years.
We believe that AffyXell will shortly be seeking external funding in a Series A round, which will provide an exact valuation for Avacta’s existing 45% stake.”
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today, save for resolution 9, the general authority to allot shares for cash.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2019 Annual Report, which is available under the Investor Documents & Presentations section of the Company's website www.avacta.com.
Given shareholders were unable to attend the Annual General Meeting as a result of the Coronavirus pandemic and Government guidance, the Company would like to advise shareholders that the most recent business updates and presentations can be found under the Investor Documents & Presentations section of the Company's website www.avacta.com.
Watch the Proactive investor interview with Avacta CEO Alastair Smith from last week, I think you’ll find Avacta has the potential (nothing guaranteed, but as close as you can get) to make money for you over the next 2-3 years.
Thanks Leisurely.
They landed in my AJ Bell Dealing account this morning, so all good :-)